Question · asked by 1 review
Hydroxyurea vs observation: Adverse events or toxicity: differences in rates of specific adverse events
- Population
- adults and children with sickle cell disease and an increased risk of stroke
- Intervention
- Hydroxyurea
- Comparison
- observation
- Outcome
- Adverse events or toxicity: differences in rates of specific adverse events
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings ‐ Hydroxyurea vs observation Adverse events or toxicity: differences in rates of specific adverse events · adults and children with sickle cell disease and an increased risk of stroke Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 22 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Hydroxyurea vs placebo · people with sickle cell disease · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.